Compare Huntington Ingalls Industries Inc (HII) vs Hims and Hers Health Inc (HIMS) Price & Performance

HII trades at $265.02, up 1.67% today, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $5.27 surpassing expectations. Recent contract wins, including a $5.1 billion aircraft carrier overhaul, bolster revenue visibility from a $57.3 billion backlog. Valuation ratios appear reasonable with a P/E of 15.78 and P/S of 0.79.

The outlook is supported by robust defense budgets and contract momentum, but technical weakness and mixed analyst sentiment (40.7% buy, 55.6% hold) suggest near-term caution. Key risks include execution on large projects and defense spending cycles. The consensus price target of $363.67 implies significant upside if operational targets are met.

HIMS stock trades at $28.06, down 5.01% on the day, reflecting bearish technical signals and negative earnings surprises in recent quarters. The company reported strong revenue growth to $2.35 billion in 2025 but swung to a net loss of -$142 million in 2026, with profitability metrics deteriorating. Multiple securities class action lawsuits filed in October 2026 create significant legal overhangs, while analyst consensus remains cautiously optimistic with a $32.17 price target despite mixed fundamental performance.

The outlook is clouded by legal risks and profitability challenges, though the 15% upside to consensus target suggests potential recovery if execution improves. Key risks include ongoing litigation outcomes and the company's ability to return to sustainable profitability amid competitive pressures in the telehealth sector.